[Combination therapy by bleomycin, methotrexate, and telecobalt irradiation in carcinoma of the oral cavity (author's transl)].
20 patients with advanced carcinomas of the oral cavity (T3NxMo) were treated at the same time with the cytostatic drugs bleomycin and methotrexate as well as with a cobalt-60-irradiation. 14 of them are tumor free after an observation period of one half to two and a half years. Among them were 4 recurrences that had to be treated surgically. 1 patient is living with a residual tumor which cannot be further treated. 5 patients died of the tumor or of other causes. The survival rate, which is 80% after 1 year, is, as a tentative result, higher than could be attained by other therapeutic measures.
D000328:Adult; D000368:Aged; D001761:Bleomycin / Q000627:therapeutic use*; D002610:Cheek; D003037:Cobalt Radioisotopes; D004359:Drug Therapy, Combination; D006801:Humans; D007573:Jaw Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008339:Mandibular Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D008441:Maxillary Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D009060:Mouth Floor; D009062:Mouth Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D011867:Radioisotope Teletherapy; D014062:Tongue Neoplasms / Q000188:drug therapy / Q000532:radiotherapy
D003037:Cobalt Radioisotopes; D001761:Bleomycin; D008727:Methotrexate
Die Behandlung des Mundhöhlenkarzinoms mit der Kombination Bleomycin, Methotrexat, Telekobaltbestrahlung. Eine Pilotstudie.